Latest News
Intelligent Bio Solutions Partners with Princebuild to Transition from Saliva Testing to Fingerprint Sweat-Based Drug Screening Across its Seven UK Sites
Princebuild joins INBS’ portfolio of over 400 accounts in 19 countries as the Company plans to enter the US market
Intelligent Bio Solutions Announces 510(k) Submission to US FDA for Fingerprint Sweat-Based Drug Screening Technology
NEW YORK, December 18, 2024 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering
Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS